Compare ONB & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONB | HALO |
|---|---|---|
| Founded | 1834 | 1998 |
| Country | United States | United States |
| Employees | 5243 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 8.8B |
| IPO Year | N/A | 2001 |
| Metric | ONB | HALO |
|---|---|---|
| Price | $22.11 | $64.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | $26.75 | ★ $78.18 |
| AVG Volume (30 Days) | ★ 3.0M | 1.3M |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.56 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | $27.97 | $28.24 |
| Revenue Next Year | $5.16 | $12.79 |
| P/E Ratio | ★ $13.92 | $24.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.83 | $47.50 |
| 52 Week High | $26.17 | $82.22 |
| Indicator | ONB | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 47.38 | 44.77 |
| Support Level | $21.71 | $63.85 |
| Resistance Level | $23.52 | $65.40 |
| Average True Range (ATR) | 0.48 | 1.60 |
| MACD | 0.11 | 0.20 |
| Stochastic Oscillator | 93.29 | 64.96 |
Old National Bancorp is a provider of lending and deposit services. The bank offers comprehensive wealth management, trust, investment advisory, brokerage, and foreign currency services. For businesses, it provides treasury management, merchant, and capital markets services as well as community development lending and equity investment solutions intended to produce jobs and revitalize its communities. It earns interest income on loans as well as fee income from the origination of loans and from providing other services to its clients.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.